3g8i: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 3: Line 3:
The entry 3g8i is ON HOLD  
The entry 3g8i is ON HOLD  


Authors: Benz, J., Bernardeau, A., Binggeli, A., Blum, D., Boehringer , M., Grether, U., Hilpert, H., Kuhn, B., Maerki, H.P., Meyer, M., Puentener, K., Raab, S., Ruf, A., Schlatter, D., Gsell, B., Stihle, M., Mohr, P.
Authors: Benardeau, A.


Description: Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes
Description: Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Mar 4 14:45:01 2009''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Mar 11 11:10:55 2009''

Revision as of 09:10, 11 March 2009

Unreleased structure

The entry 3g8i is ON HOLD

Authors: Benardeau, A.

Description: Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diabetes

Page seeded by OCA on Wed Mar 11 11:10:55 2009

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=3g8i&oldid=935181"